Free Trial
→ I'm giving you a space stock today. Free. (From Behind the Markets) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

SAB Biotherapeutics logo
$0.0074 0.00 (-26.87%)
As of 03:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SABSW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy SAB Biotherapeutics stock or one of its competitors? SAB Biotherapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Alvotech?

SAB Biotherapeutics (NASDAQ:SABSW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

In the previous week, Alvotech had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Alvotech and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.82 beat Alvotech's score of 0.46 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Very Positive
Alvotech Neutral

Summary

Alvotech beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics and Apollomics both had 1 articles in the media. SAB Biotherapeutics' average media sentiment score of 1.82 beat Apollomics' score of 1.79 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Very Positive
SAB Biotherapeutics Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

Apollomics and SAB Biotherapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Aravive?

SAB Biotherapeutics (NASDAQ:SABSW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for SAB Biotherapeutics and 0 mentions for Aravive. SAB Biotherapeutics' average media sentiment score of 1.82 beat Aravive's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Very Positive
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

SAB Biotherapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does SAB Biotherapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and SAB Biotherapeutics (NASDAQ:SABSW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, bioAffinity Technologies had 3 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for bioAffinity Technologies and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.82 beat bioAffinity Technologies' score of 0.49 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
SAB Biotherapeutics Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

bioAffinity Technologies beats SAB Biotherapeutics on 2 of the 3 factors compared between the two stocks.

How does SAB Biotherapeutics compare to BioVie?

SAB Biotherapeutics (NASDAQ:SABSW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

In the previous week, BioVie had 3 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 4 mentions for BioVie and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.82 beat BioVie's score of 0.71 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Very Positive
BioVie Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Summary

SAB Biotherapeutics and BioVie tied by winning 1 of the 2 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABSW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.97B$7.44B$12.94B
Dividend YieldN/A3.64%2.50%27.63%
P/E RatioN/A9.68192.5218.55
Price / SalesN/A1,172.38567.9576.22
Price / CashN/A122.1076.5451.88
Price / BookN/A15.9410.295.85
Net IncomeN/A-$22.69M$3.50B$380.67M
7 Day PerformanceN/A-8.67%-5.37%-4.97%
1 Month PerformanceN/A-14.11%-8.55%-6.95%
1 Year PerformanceN/A0.66%0.43%-5.99%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.01
-26.9%		N/A-75.8%$0.00N/AN/A86
ALVOW
Alvotech
N/A$0.45
flat		N/A-71.9%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
-3.8%		N/A-64.2%$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.36
+18.3%		N/A-2.8%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 10/16/2026 by MarketBeat.com Staff.
From Our Partners
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...
Brownstone Research | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...
Profits Run | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel